Abstract:Familial dysautonomia (FD) is an autosomal recessive neurodegenerative disease that affects the development and survival of sensory and autonomic neurons. FD is caused by an mRNA splicing mutation in intron 20 of the IKBKAP gene that results in a tissue-specific skipping of exon 20 and a corresponding reduction of the inhibitor of kappaB kinase complex-associated protein (IKAP), also known as Elongator complex protein 1. To date, several promising therapeutic candidates for FD have been identified that target the underlying mRNA splicing defect, and increase functional IKAP protein. Despite these remarkable advances in drug discovery for FD, we lacked a phenotypic mouse model in which we could manipulate IKBKAP mRNA splicing to evaluate potential efficacy. We have, therefore, engineered a new mouse model that, for the first time, will permit to evaluate the phenotypic effects of splicing modulators and provide a crucial platform for preclinical testing of new therapies. This new mouse model, TgFD9; Ikbkap(Δ20/flox) was created by introducing the complete human IKBKAP transgene with the major FD splice mutation (TgFD9) into a mouse that expresses extremely low levels of endogenous Ikbkap (Ikbkap(Δ20/flox)). The TgFD9; Ikbkap(Δ20/flox) mouse recapitulates many phenotypic features of the human disease, including reduced growth rate, reduced number of fungiform papillae, spinal abnormalities, and sensory and sympathetic impairments, and recreates the same tissue-specific mis-splicing defect seen in FD patients. This is the first mouse model that can be used to evaluate in vivo the therapeutic effect of increasing IKAP levels by correcting the underlying FD splicing defect.

Loss of mouse Ikbkap, a subunit of elongator, leads to transcriptional deficits and embryonic lethality that can be rescued by human IKBKAP

Deletion of exon 20 of the Familial Dysautonomia gene Ikbkap in mice causes developmental delay, cardiovascular defects, and early embryonic lethality

A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect

Cloning, characterization, and genomic structure of the mouse Ikbkap gene

Loss of Ikbkap Causes Slow, Progressive Retinal Degeneration in a Mouse Model of Familial Dysautonomia

Sensory and autonomic deficits in a new humanized mouse model of familial dysautonomia

Ikbkap/Elp1 deficiency causes male infertility by disrupting meiotic progression

Loss-of-function of IKAP/ELP1: could neuronal migration defect underlie familial dysautonomia?

IKAP deficiency in an FD mouse model and in oligodendrocyte precursor cells results in downregulation of genes involved in oligodendrocyte differentiation and myelin formation

Peripheral Neuropathy and Hindlimb Paralysis in a Mouse Model of Adipocyte-Specific Knockout of Lkb1.

IKAP expression levels modulate disease severity in a mouse model of familial dysautonomia

IKAP/Elp1 is required in vivo for neurogenesis and neuronal survival, but not for neural crest migration

IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration

[Molecular and cellular characterization ion of IKAP protein and the Elongator complex. Implications for familial dysautonomia]

Retina-specific loss of Ikbkap/Elp1 causes mitochondrial dysfunction that leads to selective retinal ganglion cell degeneration in a mouse model of familial dysautonomia

ELP1 Splicing Correction Reverses Proprioceptive Sensory Loss in Familial Dysautonomia

IKBKAP mRNA in peripheral blood leukocytes: a molecular marker of gene expression and splicing in familial dysautonomia

Kcnh2 Deletion is Associated with Rat Embryonic Development Defects Via Destruction of KCNH2‑integrin Β1 Complex.

Loss of the Familial Dysautonomia gene in cerebellar granule cell progenitors leads to ataxia in mice

RBM24 promotes U1 snRNP recognition of the mutated 5' splice site in the IKBKAP gene of familial dysautonomia

Antisense oligonucleotides correct the familial dysautonomia splicing defect in IKBKAP transgenic mice